Roche’s Patent License Deal with Structure Therapeutics for CT-996 Obesity Drug
Roche, through Genentech, signed a patent license agreement with Structure Therapeutics' subsidiary Gasherbrum on December 30, 2025, announced January 5, 2026 via SEC filing.
The non-exclusive license covers patents related to Roche's investigational oral obesity drug CT-996, allowing make, use, sell, offer for sale, and import.
Roche pays $100 million upfront plus low-single-digit royalties on net sales of CT-996 products.
The deal includes a covenant not to assert certain future patents against Genentech and affiliates.
Analysts view it as a mild positive for Structure, validating its strong IP in GLP-1 agonists, but not a full partnership.
CT-996 originates from Roche's $2.7B acquisition of Carmot Therapeutics; early data showed 6.1% placebo-adjusted weight loss at 4 weeks.
Structure's aleniglipron showed 11.3% placebo-adjusted weight loss at 36 weeks in Phase IIb, unrelated to this deal.